Short Interest Coverage: What Next for Alexion Pharmaceuticals Incorporated (NASDAQ:ALXN) Stock After Decrease in Shorted Shares?

November 24, 2016 - By Louis Casey   ·   0 Comments

Short Interest Coverage: What Next for Alexion Pharmaceuticals Incorporated (NASDAQ:ALXN) Stock After Decrease in Shorted Shares?

The stock of Alexion Pharmaceuticals Incorporated (NASDAQ:ALXN) registered a decrease of 7.25% in short interest. ALXN’s total short interest was 4.98 million shares in November as published by FINRA. Its down 7.25% from 5.37 million shares, reported previously. With 1.94M shares average volume, it will take short sellers 3 days to cover their ALXN’s short positions. The short interest to Alexion Pharmaceuticals Incorporated’s float is 2.23%. The stock increased 1.62% or $1.9 on November 23, hitting $118.92. About 1.65M shares traded hands. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 25.25% since April 22, 2016 and is downtrending. It has underperformed by 30.66% the S&P500.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $26.52 billion. The Firm is focused on the development and commercialization of life-transforming therapeutic products. It has a 73.09 P/E ratio. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment.

Insitutional Activity: The institutional sentiment decreased to 1.07 in 2016 Q2. Its down 0.12, from 1.19 in 2016Q1. The ratio worsened, as 51 funds sold all Alexion Pharmaceuticals, Inc. shares owned while 155 reduced positions. 58 funds bought stakes while 188 increased positions. They now own 212.84 million shares or 4.67% less from 223.26 million shares in 2016Q1.
Mutual Of America Management Ltd Liability Co has invested 0.07% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). The California-based Financial Advisers Lc has invested 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Dimensional Fund Advsr L P has invested 0.02% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Polar Capital Limited Liability Partnership accumulated 0.02% or 9,520 shares. Goldman Sachs Grp Inc Inc holds 0.06% or 1.45M shares in its portfolio. Reliance Of Delaware, a Delaware-based fund reported 10,528 shares. Ftb Advisors Inc has 306 shares for 0% of their US portfolio. Congress Asset Mngmt Comm Ma holds 0.09% or 34,525 shares in its portfolio. Lombard Odier Asset Mgmt (Europe) Limited accumulated 0.02% or 2,794 shares. Moreover, Kistler has 0% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 16 shares. Parkside Fincl Bank Tru accumulated 0% or 5 shares. Tarbox Group Inc accumulated 0% or 43 shares. Pub Employees Retirement Association Of Colorado has 47,923 shares for 0.05% of their US portfolio. Amalgamated Financial Bank accumulated 0.15% or 19,518 shares. Qs Investors holds 27,777 shares or 0.03% of its portfolio.

Insider Transactions: Since June 13, 2016, the stock had 0 buys, and 19 insider sales for $9.39 million net activity. Shares for $221,078 were sold by BELL LEONARD on Monday, October 31. $125,940 worth of shares were sold by Thiel Carsten on Tuesday, September 6. Another trade for 165 shares valued at $22,628 was sold by Carmichael Clare. On Monday, August 15 PARVEN ALVIN S sold $2.14 million worth of the stock or 15,700 shares. Shares for $82,089 were sold by O’Neill Julie. $47,093 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by Miller Edward. Shares for $30,445 were sold by Wagner Heidi L.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Out of 20 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 15 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 75% are positive. Alexion Pharmaceuticals Inc. has been the topic of 40 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Citigroup initiated Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Thursday, February 25 with “Neutral” rating. Suntrust Robinson initiated the shares of ALXN in a report on Thursday, January 7 with “Buy” rating. UBS maintained the shares of ALXN in a report on Thursday, February 4 with “Buy” rating. The rating was initiated by Deutsche Bank with “Buy” on Thursday, November 3. JP Morgan initiated the stock with “Overweight” rating in Monday, July 27 report. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Neutral” rating by Wedbush on Friday, September 23. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Mkt Perform” rating by FBR Capital on Friday, October 28. Goldman Sachs upgraded the shares of ALXN in a report on Friday, October 28 to “Buy” rating. Wedbush maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Friday, October 28 with “Neutral” rating. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by SunTrust on Thursday, January 7.

ALXN Company Profile

Alexion Pharmaceuticals, Inc., incorporated on January 28, 1992, is a biopharmaceutical company. The Firm is focused on the development and commercialization of life-transforming therapeutic products. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500.

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Businesswire.com which released: “Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders …” on November 22, 2016, also Prnewswire.com with their article: “ALEXION NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered …” published on November 16, 2016, Businesswire.com published: “Alexion Receives NASDAQ Notification Related to the Late Filing of Form 10-Q” on November 16, 2016. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Marketwatch.com and their article: “Alexion Pharma shares halted, company to delay quarterly results” published on November 09, 2016 as well as Globenewswire.com‘s news article titled: “SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Alexion …” with publication date: November 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>